Effect of cooked rice with added fructo-oligosaccharide on faecal microorganisms investigated by in vitro digestion and fermentation

In the present study,the effects of cooked rice(CR)with added fructo-oligosaccharide(FOS)on faecal flora were studied by a simulated in vitro digestion and fermentation method.The total carbohydrate content,p H,and s hort-chain fatty acids(SCFAs)were determined during in vitro digestion and fermentation.The change in the bacterial phase distribution after the fermentation was also analysed.The results showed that t he total carbohydrate content of the CR with added FOS(FCR)significantly decreased during the simulated digestion.Meanwhile,the p H of the FCR decreased and the SCFAs concentration increased significantly compared to those of the CR during the simulated fermentation.In addition,the FCR showed the advantage of promoting beneficial bacteria,such as Bifidobacterium and Lactobacillus,and inhibiting harmful bacteria,such as Bacteroides and Klebsiella compared to the CR.Therefore,the FOS as a prebiotic could be recommended to produce the high-quality healthy rice food.

Optimization of the Solid-phase Fermentation Medium of Metarhizium flavoviride by Response Surface Method

Rice flour, puparium of yellow mealworm, peanut shell and sunflower seed shell are made into the culture medium, and the optimal solid-phase fermen- tation formula for M. flavoviride is figured out. In the solid-phase fermentation, Design-Expert is applied to analyze the significance of all components on the sporu- lotion, and response surface method used to optimize the fermentation medium of M. flavoviride. The results show that puparlum of yellow mealworm is the most sig- nificant component for the sporulation; and the optimal medium formula for the fermentation of M. flavoviride： 0.25-g rice flour, 0. 14-g yellow mealworm pupari- urn, 1.00-g peanut shell, and 0.25-g sunflower seedshell. In this optimal medium, the sporulation achieves 100. 013 × 10^8 spores/mL fungal liquid, 31.7% higher than that of the initial design. Application of the optimal formula will reduce the production cost, obtain higher yield of spores, produce no pollution, and offer tech- nical support for the future large-scale production.

基于改进NSGA-Ⅱ的交叉口信号配时多目标优化

针对城市交叉口信号配时多目标优化的求解效率问题,设计了一种基于改进NSGA-Ⅱ的城市交叉口信号配时优化方案。该方法采纳车辆延误、停车次数、通行能力3个评价指标设计了多目标信号配时优化模型,并提出了改进的NSGA-Ⅱ(NSGA-Ⅱ-DE)对配时模型进行求解。NSGA-Ⅱ-DE采用DE/Rand/1的全局变异策略对NSGA-Ⅱ算法选择策略进行改进,并设计了种群动态更新算法,提高了算法的收敛速度和求解精度。结果表明改进算法获得了较好的Pareto最优解,通过典型交叉口仿真验证,相对于NSGA-Ⅱ算法,NSGA-Ⅱ-DE方法设计配时方案平均车辆延误优化提升13.42%,排队长度优化提升16.73%,平均停车次数优化提升15.50%,能够实现城市交叉口的最优化控制。

强组合PhaseⅠ－PhaseⅡ次可行方向法

本文对Ｐｏｌａｋ等人的组合ＮａｓｅⅠ－Ⅱ可行方向法进行改进，使之不仅能自动地将初始化阶段（Ｐｈａｓｅｌ）和最优化阶段（ＰｈａｓｅⅡ）统一起来，而且保证了满足不等式约束的函数个数不断叠累递增，故称改进后的算法为强组合ＰｈａｓｅⅠ－ⅡＰｈａｓｅⅡ次可行方向法．本文算法包含了一种新的目标局数非单词的非精确线搜索，它保证了算法产生的点列的任何聚点都是问题的Ｋ－Ｔ的点．

Phase Ⅱ open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Background: Despite the recent development of new therapies, multiple myeloma(MM) remains an incurable disease. Thus, new, efective treatments are urgently needed, particularly for relapsed or refractory MM(RRMM). In an earlier phase I study, a novel form of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) that is currently in clinical development for the treatment of hematologic malignancies, i.e., circularly permuted TRAIL(CPT), was well tolerated at a dose of 2.5 mg/kg per day and showed promising preliminary activity in patients with RRMM. This phase II, open-label, multicenter study further investigated the eicacy and safety of 2.5-mg/kg per day CPT as single-agent therapy for patients with RRMM.Methods: Patients with RRMM were treated once daily with CPT(2.5 mg/kg, intravenously) for 14 consecutive days for each 21-day cycle. Clinical response and toxicity were assessed after each treatment cycle.Results: Twenty-seven patients received CPT. Using the European Group for Blood and Marrow Transplantation criteria, we calculated the overall response rate of 33.3% with 1 near-complete response(n CR) and 8 partial responses(PRs). The clinical beneit rate(48.1%) included 1 nCR, 8 PRs, and 4 minimal responses. The most common treatmentrelated adverse events(TRAEs) were fever, aspartate aminotransferase elevation, alanine aminotransferase elevation, leucopenia, rash, neutropenia, and thrombocytopenia. We graded toxicity using the Common Toxicity Criteria for Adverse Events, version 3.0, and determined that 37.0% of patients had at least 1 grade 3–4 TRAE.Conclusions: CPT as a single agent can elicit a response in patients with RRMM and is well tolerated. Further clinical investigation is warranted.

Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine(GEM)-refractory unresectable pancreatic cancer(PC).METHODS This study was a prospective, multicenter, one-arm, open-label, phase Ⅱ trial. Patients with unresectable PC, who showed disease progression during GEMbased chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin(RIO; irinotecan 120 mg/m^2 and oxaliplatin 60 mg/m^2), which was set according to the phase Ⅰ study of FOLFIRINOX. The objective response rate(ORR), disease control rate(DCR), progressionfree survival(PFS), overall survival(OS), adverse events were evaluated. Additionally, changes in quality of life(QoL) were assessed using a questionnaire on QoL.RESULTS Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [95% confidence interval(CI): 3.7-7.9] and median OS was 9.0 mo(95%CI: 6.4-11.6). Neutropenia(64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia(16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment(45.43 ± 22.88 vs 48.66 ± 24.14, P = 0.548).CONCLUSION FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities.

Total synthesis of human urotension-Ⅱ by microwave-assisted solid phase method

Human urotension-Ⅱ was synthesized efficiently on Wang resin under microwave irradiation using Fmoc/tBu orthogonal protection strategy. Disulphide bridge was formed on solid phase with the irradiation of microwave, then the whole peptide was cleaved from the resin. The purity of crude peptide cyclized under microwave irradiation was higher than that under room temperature.

Phase Transfer Research for Heteropolyanions Containing Cr（Ⅲ），Mn（Ⅳ），Co（Ⅱ），Zn（Ⅱ）

ＰｈａｓｅＴｒａｎｓｆｅｒＲｅｓｅａｒｃｈｆｏｒＨｅｔｅｒｏｐｏｌｙａｎｉｏｎｓＣｏｎｔａｉｎｉｎｇＣｒ（Ⅲ），Ｍｎ（Ⅳ），Ｃｏ（Ⅱ），Ｚｎ（Ⅱ）ＺＨＡＮＧＳｈｕ－ｙｕｎ；ＨＵＡＮＧＲｕ－ｄａｎ；ＹＵＸｉｎ－ｗｕ；ＬＩＢａｉｔａｏａｎｄＷＡＮＧＥｎ－...

PHASE Ⅱ STUDY OF GEMCITABINE COMBINED WITH PLATINUM CHEMOTHERAPY FOR RECURRENT EPITHELIAL OVARIAN CANCER

Objective To evaluate the anti-tumor effect and toxicity of gemcitabine combined with platinum chemotherapy on recurrent epithelial ovarian cancer. Methods Phase Ⅱstudy of gemcitabine combined with platinum chemotherapy was carried out in 22 patients with recurrent epithelial ovarian cancer. Median age of patients was 50.5 years old. Seven patients were platinum-sensitive and 15 patients were platinum-resistant or -refractory. All patients received gemcitabine combined with carboplatin or oxaliplatin chemotherapy. Patients' response rate (RR) and toxicity of gemcitabine combined with platinum chemotherapy were evaluated. Results A total of 98 gemcitabine-based chemotherapy cycles were performed. Total RR was 36.4%, RR of platinum-sensitive patients was 4/7 and platinum-resistant and -refractory patients was 4/15. The estimated median survival time was 10.0 months (95%CI: 7.0-13.0) after initiation of gemcitabine combined with platinum chemotherapy. There was no significant difference in survival time between platinum-resistant/refractory group and platinum-sensitive group (P=0.061). Side effects of gemcitabine combined with platinum chemotherapy were observed in 81.8% of patients. Grade Ⅱ/Ⅲ anemia (54.5%) and grade Ⅲ/Ⅳ neutropenia (54.5%) were most common toxicities. Ten (45.5%) patients had to delay their chemotherapy cycles or reduce the dose of chemotherapeutic drugs because of the severe side effects. Fourteen (63.6%) patients received granulocyte colony-stimulating factor to relieve neutropenia, and 8 (36.4%) patients received component blood transfusion to treat anemia or thrombocytopenia. There was no treatment-associated death. Conclusion Gemcitabine combined with platinum chemotherapy appears to be an effective and well-tolerant treatment for recurrent epithelial ovarian cancer, including platinum-resistant or -refractory diseases.

Self-reliance and Innovation of Qinshan Phase Ⅱ NPP Project

This article mainly describes the self-reliance and innovation of Qinshan nuclear power project of phase II,in-between it contains new reactor core design,as well as related experimental and calculation analysis,especially for new reactor design produced fluid-induced vibration model test,theoretical analysis and testing in-built reactor;aiming at two-loop NSSS a series improvement made for safety systems and related safety analysis to enhance their reliability and redundancy;according to specialty of two-loop NSSS an optimization made for NPP parameters and design of related equipments,for the purpose to make the output of NPP maximal;design of main reactor building and T-G building also improved according to characteristics of two-loop NSSS and site conditions.CRDM and refueling machine are researched and manufactured on base of self-reliance,their performance are better than design requirements,large portion of key equipments are localized through different way.In construction first time realized the integrated erection of containment dome.During the commissioning non-nuclear steam driving of T-G set,as well as 500 kV high voltage rising using emergent diesel generator,etc.are carried out.In period of operation still continuous innovation and improvement are made,so that to keep the good record of operation.

TITE(e)-U-Keyboard两阶段Ⅰ/Ⅱ期试验设计研究

目的针对肿瘤靶向制剂和细胞免疫疗法治疗效应延迟的问题,基于Ⅰ/Ⅱ期试验设计框架,构建创新试验设计方法TITE(e)-U-Keyboard。方法采用二项近似似然法纳入尚未观测到的有效性结局信息,构建近似分布,辅助决策,并将TITE(e)-U-Keyboard同Ⅰ/Ⅱ期试验设计方法U-BOIN、BOIN12从多个角度进行模拟比较研究。结果模拟结果显示在考虑有效性结局延迟的情况下三种方法的OBD选择准确率及最优剂量分配受试者数相当,但TITE(e)-U-Keyboard所需试验时长最短;敏感性分析表明有效性观察窗会对TITE(e)-U-Keyboard试验时长产生影响,且随着有效性观察窗的增加而增加。结论TITE(e)-U-Keyboard在保持良好试验设计性能的同时显著缩短了试验时长,可以解决Ⅰ/Ⅱ期临床试验中治疗效应延迟的问题,加速临床试验进程。

Analysis of Bacterial Communities Present in Agaricus bisporus Phase Ⅱ Compost Using Amplified Ribosomal DNA Restriction Analysis(ARDRA)(Ⅱ)——Analysis of Bacterial Communities

Changes in the bacterial communities inhabiting Agaricus bisporus compost during Phase Ⅱ treatment were monitored using amplified rDNA restriction analysis(ARDRA).Sequence analysis data indicated that the bacterial communities associated with the compost samples were far richer in composition when determined by ARDRA compared with traditional methods based on bacterial isolation.Furthermore,the composition of the communities,especially in terms of the dominant bacteria during each of the four treatment stages(beginning of Phase Ⅱ,after pasteurization,5 days aeration,end of Phase Ⅱ,respectively),were very different.Restriction endonuclease digestion of mainly bacterial clones from four 16S rDNA libraries,C1,C3,C6 and C7,previously constructed on the basis of 16S rDNA fragments amplified from the four different stages of the Phase Ⅱ composting process,revealed the presence of unique microbial types.Thermophilic bacteria belonging to the Bacilli,and previously unreported strains of Trichococcus,Planococcus,Caryophanon,and subclass γ-Proteobacteria,were identified among the clones from the compost sampled during the aeration period(C6).Bacteria belonging to Thermus thermophilus and subclass α-Proteobacteria were detected in C1 and C7 composts sampled at the beginning and the end of Phase Ⅱ,respectively.Clones of some uncultured bacteria were also scored.

ORP阶段性控制提高葡萄酒中链脂肪酸乙酯和高级醇含量研究

氧化还原电位(Oxidation-reduction potential,ORP)反映了发酵系统的氧化还原状态,与酵母代谢以及香气化合物合成密切相关,其水平在各酒精发酵阶段存在差异。为了实现ORP在不同发酵阶段的科学控制,通过气相色谱-质谱(Gas chromatography-mass spectrometry,GC-MS)和感官量化分析法在葡萄酒酒精发酵的不同阶段控制不同水平的ORP,观察酵母生长、香气化合物合成以及感官品质的变化。结果表明,在0~48 h阶段ORP的变化对酵母活菌数和香气化合物含量的影响远高于其他阶段。提高此阶段ORP有利于酵母生长和糖消耗,而较低ORP有利于香气化合物合成。与对照相比,0 mV(0~48 h)-自然条件(48~96 h)-自然条件(96 h至发酵结束)处理组可显著提高中链脂肪酸乙酯中的己酸乙酯、癸酸乙酯含量;0 mV-0 mV-60 mV处理组可显著提高乙酸酯含量;60 mV-0 mV-60 mV处理组可显著提高高级醇含量。0 mV-自然条件-自然条件处理增强了赤霞珠葡萄酒中红色水果香气和爱格丽葡萄酒花果类香气,并减弱了爱格丽葡萄酒的动物类气味。ORP的阶段性控制为葡萄酒发酵过程的精准调控提供了依据,为提高葡萄酒香气化合物含量以改善葡萄酒的香气质量提供了基础。

国产奥沙利铂治疗大肠癌Ⅱ期临床研究

目的:评价国产注射用奥沙利铂单药及与5-氟尿嘧啶(5-Fu)-四氢叶酸(CF)联合用于治疗大肠癌的疗效及毒副反应。方法:收治带瘤大肠癌患者49例,按随机方法,分别入单药组11例(单用奥沙利铂),联合组20例(奥沙利铂+5—Fu+CF),和对照组18例(5—Fu+CF)。结果:单药组有效率27.3％,联合组30.0％,对照组5.6％,单药组和联合组疗效高于对照组,且奥沙利铂对大肠癌常见转移部位如肝脏、腹腔淋巴结、盆腔及肺脏均可见临床疗效,毒副反应主要为神经感觉异常,其中重度异常单药组为9％,联合组为10％。结论:国产注射用奥沙利铂单用或联合5—Fu、CF治疗大肠癌疗效肯定,耐受性良好,值得临床进一步研究和扩大应用。

不同基因型可可发酵过程中挥发性香气成分变化规律研究

挥发性香气成分组成是可可品质评价的重要指标之一,而发酵是影响可可挥发性香气成分的关键过程。为揭示不同基因型可可豆发酵过程中挥发性香气成分的变化规律及差异,本研究以ZYP11-9、STS16、ZYP6-11三种不同基因型可可作为试验材料,利用顶空固相微萃取-气相色谱-质谱联用技术(HS-SPME-GC/MS)测定可可豆0~7 d发酵过程中的挥发性香气成分,并采用峰面积归一化法计算各成分的相对含量。结果表明:3种基因型可可豆发酵过程中共鉴定出32种挥发性香气成分,其中2,3-丁二醇、2-庚醇、2-戊醇、3-甲基-1-丁醇、苯乙醇、芳樟醇、乙酸、3-羟基-2-丁酮及2,3,5-三甲基吡嗪9种共有香气物质在不同基因型可可豆发酵过程中的相对含量变化存在显著差异;主成分分析表明,主要香气成分与发酵阶段香气特征之间存在一定相关性,其中2,3-丁二醇、乙酸、芳樟醇、3-羟基-2-丁酮与可可豆发酵阶段香气特征呈正相关,3-甲基-1-丁醇、丁内酯、苯乙酮等香气物质与发酵阶段香气特征呈负相关。因此,不同基因型可可发酵过程中的香气成分组成及含量变化存在差异,且主要香气成分与发酵阶段存在相关性,这为优质可可新品种选育及应用提供参考依据。

多联吡啶螯合物反相高效液相色谱法分离测定铜(Ⅱ)、钴(Ⅱ)、汞(Ⅱ)

以三联吡啶衍生物６，６”－二甲基－４＇－苯基－２，２＇：６＇，２”－三联吡啶（ＴＰＹ）作柱前显色剂，于ＡｃｃＱ－Ｔａｇ柱上，用内含２．０×１０～（－６）ｍｏｌ／Ｌ ＴＰＹ和０．６ ｍｏｌ／Ｌ ＮａＡｃ－ＨＡｃ缓冲溶液（ｐＨ＝３．５）的甲醇－水溶液（５５：４５，Ｖ／Ｖ）作流动相，流速为１．０ ｍＬ／ｍｉｎ，并以紫外－可见检测器于３１０ｎｍ处进行检测，开发了一种 ＲＰ－ＨＰＬＣ法同时分离测定铜（Ⅱ）、钴（Ⅱ）、汞（Ⅱ）的方法。该方法简便快速，灵敏度高，对于铜、钴、汞的检测限分别是０．００２０、０．００５５和０．００４０ｍｇ／Ｌ。用于实际样品测定，结果满意。

2-(2-噻吩偶氮)-5-二乙氨基酚反相液相色谱法分离测定铜(Ⅱ)、钴(Ⅱ)、镍(Ⅱ)

本文以2-(2-噻吩偶氮)-5-二乙氨基酚(简称TADAP)作柱前显色剂,反相色谱法分离测定铜(Ⅱ)、钴(Ⅱ)、镍(Ⅱ)离子。用含有1.5×10^(-4)mol/L的TADAP,0.1mol/L氯化锂和0.1mol/L乙酸盐(pH4)的甲醇(60％)-水(40％)溶液作为流动相,流量为0.9ml/min,紫外-可见检测器检测波长为545nm。在此条件下,铜(Ⅱ)、钴(Ⅱ)、镍(Ⅱ)螯合物得到最佳分离,并定量测定了茶叶中铜、钴、镍的含量,与原子吸收分光光度法测定,得到一致的结果。

国产唑来膦酸治疗肿瘤高钙血症多中心Ⅱ期临床观察

目的:评价国产注射用唑来膦酸治疗肿瘤高钙血症的临床疗效和安全性。方法:采用多中心、开放临床研究对15例肿瘤性高钙血症患者给予唑来膦酸4mg静脉滴注15min治疗,在28天内定期观察血钙的变化和不良反应。结果:1例患者因依从性差出组,可评价疗效14例。有效缓解率,即校正血钙降至正常,为100%(14/14),有效缓解中位时间为5.07天,缓解的中位维持时间22.30天。不良反应主要有轻中度发热。结论:国产注射用唑来膦酸能够快速、有效、持久的降低恶性肿瘤高钙血症,使用安全、方便。

发酵桦褐孔菌对链脲佐菌素诱导的Ⅱ型糖尿病大鼠降血糖作用的影响

通过高脂饮食联合腹腔注射链脲佐菌素(streptozotocin,STZ)的方法建立Ⅱ型糖尿病(type 2diabetes mellitus,T2DM)大鼠模型,探讨发酵桦褐孔菌(fermented Inonotus obliquus,FIO)对T2DM大鼠的血糖、血脂及抗氧化作用的影响。结果表明:与模型组相比较,FIO可显著降低T2DM大鼠的空腹血糖(fasting blood glucose,FBG)、促进肝糖原(hepatic glycogen,HGln)合成、改善胰岛素(insulin,INS)抵抗,使总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、游离脂肪酸(free fatty acids,FFA)、低密度脂蛋白(low density lipoprotein,LDL)及丙二醛(malondialdehyde,MDA)含量显著下降,高密度脂蛋白(high density lipoprotein,HDL)含量和超氧化物歧化酶(superoxide dismutase,SOD)的活性显著上升。说明FIO能够降低Ⅱ型糖尿病大鼠血糖,改善脂质代谢及氧化应激水平。